- Home
- MNPR vs VOXR Comparison
MNPR vs VOXR Comparison
Compare MNPR & VOXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- VOXR
- Stock Information
- Founded
- MNPR 2014
- VOXR 2014
- Country
- MNPR United States
- VOXR United States
- Employees
- MNPR N/A
- VOXR N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- VOXR Precious Metals
- Sector
- MNPR Health Care
- VOXR Basic Materials
- Exchange
- MNPR Nasdaq
- VOXR Nasdaq
- Market Cap
- MNPR 209.3M
- VOXR 168.0M
- IPO Year
- MNPR 2019
- VOXR N/A
- Fundamental
- Price
- MNPR $35.17
- VOXR $3.16
- Analyst Decision
- MNPR Strong Buy
- VOXR
- Analyst Count
- MNPR 6
- VOXR 0
- Target Price
- MNPR $59.60
- VOXR N/A
- AVG Volume (30 Days)
- MNPR 55.8K
- VOXR 667.9K
- Earning Date
- MNPR 08-08-2025
- VOXR 08-06-2025
- Dividend Yield
- MNPR N/A
- VOXR 1.55%
- EPS Growth
- MNPR N/A
- VOXR N/A
- EPS
- MNPR N/A
- VOXR N/A
- Revenue
- MNPR N/A
- VOXR $10,845,445.00
- Revenue This Year
- MNPR N/A
- VOXR $16.51
- Revenue Next Year
- MNPR N/A
- VOXR $4.60
- P/E Ratio
- MNPR N/A
- VOXR N/A
- Revenue Growth
- MNPR N/A
- VOXR N/A
- 52 Week Low
- MNPR $1.72
- VOXR $2.21
- 52 Week High
- MNPR $54.30
- VOXR $3.79
- Technical
- Relative Strength Index (RSI)
- MNPR 51.51
- VOXR 38.24
- Support Level
- MNPR $31.17
- VOXR $3.10
- Resistance Level
- MNPR $35.01
- VOXR $3.71
- Average True Range (ATR)
- MNPR 2.10
- VOXR 0.15
- MACD
- MNPR 0.11
- VOXR -0.07
- Stochastic Oscillator
- MNPR 46.49
- VOXR 9.68
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.